High-throughput screening (HTS) for potential anticancer agents requires a broad portfolio of assay platforms that may include kinase enzyme assays, protein-protein binding assays, and functional cell-based apoptosis assays. The authors have explored the use of fluorometric microvolume assay technology (the FMAT™ 8100 HTS System) in three distinct homogeneous HTS assays: (1) a Src tyrosine kinase enzyme assay, (2) a Grb2-SH2 protein-peptide interaction assay, and (3) an annexin V binding apoptosis assay. Data obtained from all three assays suggest that the FMAT system should facilitate the implementation of homogeneous assays for a wide variety of molecular targeted and cell-based screens. (Journal of Biomolecular Screening 2003:81-88)
Gibbs JB: Mechanism-based target identification and drug discovery in cancer research . Science2000;287:1969-1973.
2.
Hanahan D., Weinberg RA: The hallmarks of cancer. Cell2000 ;100:57-70.
3.
Miraglia S., Swartzman EE, Mellentin-Michelotti J., Evangelista L., Smith C., Gunawan I., et al: Homogeneous cell- and bead-based assays for high throughput screening using fluorometric microvolume assay technology. J Biomol Screen1999;4:193-204.
4.
Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol1997;13:513-609.
5.
Bolen JB, Brugge JS: Leukocyte protein tyrosine kinases: potential targets for drug discovery . Annu Rev Immunol1997;15:371-404.
6.
Luttrell DK, Lee A., Lansing TJ, Crosby RM, Jung KD, Willard D., et al: Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci USA1994;91:83-87.
7.
Buday L., Downward J.: Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor . Cell1993;73:611-620.
8.
Ettmayer P., France D., Gounarides J., Jarosinski M., Martin MS, Rondeau JM, et al: Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2(1). J Med Chem1999;42:971-980.
9.
Swartzman EE , Miraglia SJ, Mellentin-Michelotti J., Evangelista L., Yuan PM: A homogeneous and multiplexed immunoassay for high-throughput screening using fluorometric microvolume assay technology. Anal Biochem1999;271:143-151.
10.
Wyllie AH, Kerr JF, Currie AR: Cell death: the significance of apoptosis. Int Rev Cytol1980;68:251-306.
11.
Ellis RE, Yuan JY, Horvitz HR: Mechanisms and functions of cell death. Annu Rev Cell Biol1991;7:663-698.
12.
Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, et al: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol1992;148:2207-2216.
13.
Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, et al: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med1995;182:1545-1556.
14.
Tait JF, Gibson D., Fujikawa K.: Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family. J Biol Chem1989;264:7944-7949.
15.
Andree HA, Reutelingsperger CP, Hauptmann R., Hemker HC, Hermens WT, Willems GM: Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers. J Biol Chem1990;265:4923-4928.
16.
Raynal P., Pollard HB: Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta1994;1197:63-93.
17.
Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C: A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods1995 ;184:39-51.
18.
Lydon NB, Gay B., Mett H., Murray B., Liebetanz J., Gutzwiller A., et al: Purification and biochemical characterization of non-myristoylated recombinant pp60c-src kinase. Biochem J1992 ;287:985-993.
19.
Druker BJ, Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest2000;105:3-7.
20.
Tamaoki T., Nomoto H., Takahashi I., Kato Y., Morimoto M., Tomita F.: Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase . Biochem Biophys Res Commun1986;135:397-402.
21.
Mellentin-Michelotti J., Evangelista LT, Swartzman EE, Miraglia SJ, Werner WE, Yuan PM: Determination of ligand binding affinities for endogenous seven-transmembrane receptors using fluorometric microvolume assay technology. Anal Biochem1999;272:182-190.
22.
Martens C., Bakker A., Rodriguez A., Mortensen RB, Barrett RW: A generic particle-based nonradioactive homogeneous multiplex method for high-throughput screening using microvolume fluorimetry. Anal Biochem1999;273:20-31.
23.
Zuck P., Lao Z., Skwish S., Glickman JF, Yang K., Burbaum J., et al: Ligand-receptor binding measured by laser-scanning imaging. Proc Natl Acad Sci USA1999;96:11122-11127.
